Last reviewed · How we verify
NCT05455749
Effect of holoBLG on Cat Allergic Patients
NA trial testing holoBLG in Allergy to Cats in 42 participants. Completed in 16 March 2022.
15 March 2022
Quick facts
| Lead sponsor | Allergy Therapeutics |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 42 |
| Start date | 4 October 2021 |
| Primary completion | 15 March 2022 |
| Estimated completion | 16 March 2022 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- holoBLG
Conditions studied
- Allergy to Cats — all drugs for Allergy to Cats →
- Allergic Rhinoconjunctivitis — all drugs for Allergic Rhinoconjunctivitis →
Sponsor
Allergy Therapeutics — full company profile →
Who can join
Adults 18 to 65, any sex, with Allergy to Cats or Allergic Rhinoconjunctivitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to investigate the antigen-unspecific effect of a 3 months supplementation with a food for special medical purposes (FSMP) in form of a lozenge containing beta-lactoglobulin (BLG), iron, retinoic acid, zinc and polyphenols (holo-BLG) in patients with allergic rhinoconjunctivitis caused by cat (hair/dander) and the associated symptoms (symptom type and severity) during exposure to cat allergen in an Allergen Exposure Chamber (AEC).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Lack of iron, zinc, and vitamins as a contributor to the etiology of atopic diseases.
Peroni DG, Hufnagl K, Comberiati P, Roth-Walter F. · · 2022 · cited 56× · PMID 36698466 · DOI 10.3389/fnut.2022.1032481 -
The holo beta-lactoglobulin lozenge reduces symptoms in cat allergy-Evaluation in an allergen exposure chamber and by titrated nasal allergen challenge.
Bergmann KC, Raab J, Graessel A, Zwingers T, et al · · 2023 · cited 6× · PMID 37488734 · DOI 10.1002/clt2.12274
Verify or expand the search:
- PubMed search for NCT05455749
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Allergy Therapeutics trials
Trials by the same sponsor.
- NCT07412990 — GRASS (Grass MATA MPL Real-world Assessment Study) · recruiting
- NCT05540717 — Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass · Phase 3 · completed
- NCT04687059 — An Exploratory Study of PQ Grass 27600 SU · Phase 2, PHASE3 · completed
- NCT04389034 — Influence of Specific Immunotherapy With Pollinex Quattro (Tree-/Grass Pollen) on Allergen-specific Immunoglobulin E (Ig · completed
- NCT03931993 — A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05455749 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Allergy Therapeutics
- Last refreshed: 18 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05455749.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing